BeyondSpring Inc. (BYSI)

In the past six months, BeyondSpring's stock has been impacted by several events. BeyondSpring announced an ESMO Asia Presentation highlighting Plinabulin + Docetaxel's improved survival in a large Phase 3 DUBLIN-3 Asian subset for EGFR WT NSCLC. The company also announced new analyses from the DUBLIN-3 Phase 3 study, demonstrating a survival benefit of Plinabulin + Docetaxel in post Anti-PD-(L)1 for non-squamous EGFR WT NSCLC and a reduction in brain metastasis at NACLC 2025. BYSI's stock showed an upward trajectory, reaching peak highs of $2.18 and closing at $2.12, with intraday trading peaking at $2.44. BeyondSpring reported its Third-Quarter 2025 Financial Results and provided a corporate update. A significant shareholder, Decheng Capital China Life Sciences USD Fund III, divested 5,710 shares of BeyondSpring stock. The company reported its Second-Quarter 2025 Financial Results and provided a corporate update. Overall, the stock price as of January 2, 2026, was $1.61 per share, representing a decline of 3.01% from January 6, 2025, and the stock has been down 30.30% in the last six months.

As a clinical-stage biopharmaceutical company focused on drug development, BeyondSpring, Inc. does not experience demand seasonality in the traditional sense. The demand for BeyondSpring's products is primarily driven by the progression of its drug candidates through clinical trials, regulatory approvals, and eventual market adoption, rather than predictable seasonal purchasing patterns.

BeyondSpring, Inc. is a global clinical-stage biopharmaceutical company focused on developing cancer therapies. Its core business revolves around oncology therapeutics and drug discovery platforms. The company's lead product candidate is Plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), being developed for multiple indications, including the prevention of chemotherapy-induced neutropenia (CIN) and as an anti-cancer agent in combination therapies for non-small cell lung cancer (NSCLC) and other cancers. The company's pipeline also includes other product candidates such as BPI-002, BPI-003, and BPI-004 for various cancers and tumors, and it invests in targeted protein degradation (TPD) technologies.

BeyondSpring maintains a global presence, with its headquarters in Florham Park, New Jersey, USA. The company also has corporate operations in New York, USA, and Suzhou, China. Its operations extend through subsidiaries in the US, Hong Kong, China, the UK, Australia, and Brazil.

In the past year, BeyondSpring's reputation has been shaped by both positive clinical advancements and financial challenges. Positive developments include presentations at ESMO Asia and NACLC 2025, showcasing Plinabulin's potential to improve survival in NSCLC patients and reduce brain metastasis. The company also reported promising data from a Phase 2 study on Plinabulin's efficacy in NSCLC and received FDA clearance for SEED Therapeutics' RBM39 degrader ST-01156. A publication in Med (Cell Press) highlighted Plinabulin's mechanism in rapidly activating dendritic cells in patients across various cancer types who had previously failed immunotherapy. However, the company faces significant financial challenges, with zero revenue and negative margins, indicating severe financial distress.

BeyondSpring, Inc. has a diverse ownership structure. Institutional investors hold 14.68% of the stock, while insiders own 12.00%, and retail investors account for 73.32%. Major institutional owners include Decheng Capital LLC, BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, Llc, Northern Trust Corp, iShares Micro-Cap ETF, Decheng Capital China Life Sciences USD Fund II, L.P., and Decheng Capital China Life Sciences USD Fund III, L.P. Key individual and insider owners include Decheng Capital China Life Sciences Usd Fund III LP, Lan Huang, Jiangwen Majeti, and Patrick Fabbio.